Abstract
Epstein-Barr virus (EBV) is one of the small number of human herpesviruses (reviewed by Kieff and Liebowitz, 1990; Miller, 1990). These are complex viruses with large double-stranded DNA genomes, the EBV gene being approximately 170 Kd and coding for at least 70 genes. A prominent characteristic of these viruses in this group is that they are able to persist in a latent infectious state in humans in the face of sustained and comprehensive immune response which include virus-neutralising antibodies in the sera of infected individuals. EBV infects greater than 90% of the human population world-wide, infection usually occurring early in childhood, but in the Western world infection is frequently delayed until adolescence when there is a 50% chance of infectious mononucleosis occurring. EBV can infect only B lymphocytes and certain classes of epithelial cell by binding to the complement receptor CR2 of B lymphocytes and a similar molecule on epithelial cells (Hutt-Fletcher, 1991). The mode of infection is by horizontal transmission through an oral portal of entry leading to infection of epithelial cells in the oropharynx. It is here that the virus is able to reside in a state of productive infection generating infectious virus in the saliva which can infect other individuals. B lymphocytes in the circulation passing in the region of these infected epithelial cells become infected also but only a very small number ever progress to productive infection.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beisel, C., Tanner, J., Matsuo, T., Thorley-Lawson, D., Kedy, F. and Kieff, E., 1985, Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene, J. Virol., 54:665.
Bejarano, M. T., Masucci, M. G., Morgan, A., Morein, B., Klein, G. and Klein, E., 1990, Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation, J. Virol., 64:1398.
Byars, N. E. and Allison, A. C., 1987, Adjuvant formulation for use in vaccines to elicit both cell-mediated and humoral immunity, Vaccine, 5:223.
Byars, N. E., Nakaon, G., Welch, M., Lehman, D. and Allison, A. C., 1991, Improvement of hepatitis B vaccine by the use of a new adjuvant, Vaccine, 9:309.
Chen, C. J., Liang, K. Y., Chang, Y. S., Wang, Y. F., Hsieh, T., Hsu, M., Chen, J. Y. and Liu, M. Y., 1990, Multiple risk factors of nasopharyngeal carcinoma: Epstein-Barr virus, malarial infection, cigarette smoking and familial tendency, Anticancer Res., 10:547.
Cleary, M. L., Epstein, M. A., Finerty, S., Dorfman, R. F., Bornkamm, G. W., Kirkwood, J. K, Morgan, A. J. and Sklar, J., 1985, Individual tumors of multifocal EBV-induced malignant lymphomas in tamarins arise from different B-cell clones, Science, 228:722.
David, E. M. and Morgan, A. J., 1988, Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography, J. Immunol. Methods, 108:231.
Dillon, S. B., Demuth, S. G., Schneider, M. A., Weston, C. B., Jones, C. S., Young, J. F., Scott, M., Bhatnaghar, P. K., LoCastro, S. and Hanna, N., 1992, Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant, Vaccine, 10:309.
Emini, E. A., Schleif, W. A., Armstrong, M. E., Silberklang, M., Schultz, L. D., Lehman, D., Maigetter, R. Z., Qualtiere, L. F., Pearson, G. R. and Ellis, R. W., 1988, Antigenic analysis of the Epstein-Barr virus major membrane antigen (gp350/220) expressed in yeast and mammalian cells: implications for the development of a subunit vaccine, Virology, 166:387.
Emini, E. A., Schleif, W. A., Silbeklang, M., Lehmanm, D. and Ellis, R. W., 1989, Vero cell-expressed Epstein-Barr virus D. gp350/220 protects marmosets from EBV challenge, J. Med. Virol, 27:120.
Epstein, M. A., 1976, Epstein-Barr virus - is it time to develop a vaccine program? Journal of the National Cancer Institute, 56:697.
Epstein, M. A., Achong, B. G. and Barr, Y. M., 1964, Virus particles in cultured lymphoblasts from Burkitt’s lymphoma, Lancet, i:703.
Epstein, M. A., Morgan, A. J., Finerty, S., Randle, B. J. and Kirkwood, J. K., 1985, Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine, Nature, 318:287.
Epstein, M. A., North, J. R. and Morgan, A. J., 1983, Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form, J. Gen. Virol., 64:455.
Epstein, M. A., Randle, B. J., Finerty, S. and Kirkwood, J. K., 1986, Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals, Clin. Exp. Immunol., 63:485.
Epstein, M. A., zur Hausen, H., Ball, G. and Rabin, H., 1975, Pilot experiments with EBV in owl monkeys (Aotus trivirgatus). III: Serological and biochemical findings in an animal with reticuloproliferative disease, Int. J. Cancer, 15:17.
Facer, C. A. and Playfair, J. H., 1989, Malaria, Epstein-Barr virus, and the genesis of lymphomas, Adv. Cancer Res., 53:33.
Finerty, S., Tarlton, J., Mackett, M., Conway, M., Arrand, J. R., Watkins, P. E. and Morgan, A. J., 1992, Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector, J. Gen. Virol, 743:449.
Haddad, R. S. and Hutt-Fletcher, L. M., 1989, Depletion of glycoprotein gp85 from virosomes made with Epstein-Barr virus proteins abolishes their ability to fuse with virus receptor-bearing cells, J. Virol., 63:4998.
Hutt-Fletcher, L., 1991, Epstein-Barr virus tissue tropism: a major determinant of immunopathogenesis, Springer Seminars in Immunopathology 13:117.
Kaaden, O. R. and Dietzschold, B. 1974, Alterations of the immunological specificity of plasma membranes of cells infected with Marek’s disease and turkey herpesviruses, J. Gen. Virol., 25:1.
Kieff, E. and Liebowitz, D., 1990, Epstein-Barr virus and tis replication, in: “Virology,” B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. O. Melnick, T. P. Month and B. Roizman, eds., Raven Press, New York.
Laufs, R. and Steinke, H., 1975, Vaccination of non-human primates against malignant lymphoma, Nature, 253:71.
Lu, S., Day, N. E., Degos, L., Lepage, V., Wang, P-C., Chan, S-H., Simons, M., McKnight, B., Easton, D., Zeng, Yi and de-The, G., 1991, Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region, Nature, 346:470.
Madej, M., Conway, M. J., Morgan, A. J., Sweet, J., Wallace, L., Arrand, J. and Mackett, M., 1992, Purification and characterisation of Epstein-Barr virus gp340/220 produced by a bovine papilloma virus vector system, Vaccine, 10:777.
Magrath, I., 1990, The pathogenesis of Burkitt’s lymphoma, Adv. Cancer Res., 55:133–270.
Miller, G., 1990, Epstein-Barr virus, in: “Virology,” B. N. Fields, D. M. Knipe, R. M. Chanock, M. S. Hirsch, J. O. Melnick, T. P. Month and B. Roizman, eds., Raven Press, New York.
Morein, B., Fossum, C., Lovgren, K. and Hoglund, S., 1990, The Iscom - a modern approach to vaccines, Seminars in Virology, 1:49.
Morgan, A. J., Allison, A. C., Finerty, S., Scullion, F. T., Byars, N. E. and Epstein, M. A., 1989, Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use, J. Med. Virol., 29:74.
Morgan, A. J., Finerty, S., Lovgren, K., Scullion, F. T. and Morein, B., 1988, Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EBV envelope glycoprotein gp340 incorporated into immune-stimulating complexes, J. Gen. Virol., 69:2093.
Morgan, A. J., Mackett, M., Finerty, S., Arrand, J. R., Scullion, F. T. and Epstein, M. A., 1988, Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins aginst EBV-induced malignant lymphomas, J. Med. Virol., 25:189.
Morgan, A. J., North, J. R. and Epstein, M. A., 1983, Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form, J. Gen. Virol., 64:455.
Morgan, A. J., Smith, A. R., Barker, R. N. and Epstein, M. A., 1984, A structural investigation of the Epstein-Barr (EB) virus membrane antigen glycoprotein, gp340, J. Gen. Virol, 65:397.
Moss, D. J., Misko, I. S., Sculley, T. B., Apolloni, A., Khanna, R. and Burrows, S. R., 1991, Immune regulation of Epstein-Barr virus (EBV): EBV nuclear antigen as a target for EBV-specific T cell lysis, Springer Seminars in Immunopathology, 13:147.
Motz, M., Deby, G. and Wolf, H., 1987, Truncated versions of the two major Epstein-Barr viral glycoproteins (gp250/350) are secreted by recombinant Chinese hamster ovary cells, Gene, 58:149.
Mueller, N., Evans, A., Harris, N. L., Comstock, G. W., Jellum, E., Magnus, K., Orentriech, N., Polk, B. F. and Vogelman, J., 1989, Hodgkin’s disease and Epstein-Barr virus. altered antibody pattern before diagnosis, N. Engl. J. Med., 320:689.
Nalesnik, M. A., 1991, Lymphoproliferative disease in organ transplant recipients, Springer Seminars in Immunopatholsogy, 13:181.
O’Hagan, D. T., Rahman, D., McGee, J. P., Jeffry, H., Davies, M. C., Williams, P., Davis, S. S. and Challacombe, S. J., 1991, Biodegradable microparticles as controlled release antigen delivery systems, Immunology, 73:239.
Ooka, T., de Turenne-Tessier, M. and Stolzenberg, M. C., 1991, Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases, Springer Seminars in Immunopathology, 13:233.
Pallesen, G., Hamilton Dutoit, S. J., Rowe, M. and Young, L. S., 1991, Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease, Lancet, 337:320.
Parkin, D. M., Stjemsward, J. and Muri, C. S., 1984, Estimates for the worldwide frequency of twelve major cancers, Bulletin of the World Health Organisation, 62:163.
Pither, R. J., Zhang, C. X., Shiels, C. Tarlton, J. Finerty, S. and Morgan, A. J., 1992a, Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340, J. Virol., 66:1246.
Pither, R. J., Nolan, L., Tarlton, J., Walford, J. and Morgan, A. J., 1992b, Distribution of epitopes within the amino acid sequence of the Epstein-Barr virus major envelope glycoprotein, gp340, recognized by hyperimmune rabbit sera, J. Gen. Virol., 73:1409.
Purtilo, D. T., 1991, X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology, Springer Seminars in Immunopathology, 13:181.
Ragot, T., Tosoni-Pittoni, E., Finerty, S., Morgan, A. J. and Perricaudet, M., 1991, Recombinant adenoviruses which express the Epstein-Barr virus membrane antigen gp340/220, gp220 only or a secreted form of gp340 induce persistent virus-neutralizing antibodies in rabbits in: “Epstein-Barr Virus and Human Disease,” D. V. Ablahsi, ed., Humana Press, Clifton, New Jersey.
Ragot, T., Tosoni-Pittoni, E., de Mazancourt, S., Finerty, S., Morgan, A. J. and Perricaudent, M., 1992a, Recombinant adenoviruses which express the Epstein-Barr virus membrane antigen gp340/220 and used as a live vaccine induce persistent virus-neutralizing antibodies in rabbits, J. Gen. Virol., (submitted for publication).
Ragot, T., Finerty, S., Watkins, P., Perricaudet, M. and Morgan, A. J., 1992b, Protective immunity against EBV lymphoma in the cottontop tamarin is induced by adenovirus recombinants expressing the EBV envelope glycoprotein gp340, J. Gen. Virol., 74:501.
Schultz, L. D., Tanner, J., Hofmann, K. J., Emini, E. A., Condra, J. H., Jones, R. E., Kieff, E. and Ellis, R. W., 1987, Expression and secretion in yeast of a 400-kDa envleope glycoprotein derived from Epstein-Barr virus, Gene, 54:113.
Shope, T., Dechairo, D. and Miller, G., 1973, Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus, Proc. Natl. Acad. Sci. USA, 70:2487.
Sixbey, J. W. and Yao, Q-Y., 1992, Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism, Science, 255:1578.
Tanner, J., Whang, Y., Sample, J., Sears, A. and Kieff, E., 1988, Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes, J. Virol.,, 62:4452.
Tartaglia, J., Perkus, M. E., Taylor, J., Norton, E. K., Audonnet, J-C., Cox, W. I., Davis, S. W., Vanderhoeven, J., Meignier, B., Riviere, M., Languet, B. and Paoletti, E., 1992, NYVAC: A highly attenuated strain of vaccinia virus, Virology, 88:217.
Taylor, J., Weinberg, R., Tartaglia, J., Richardson, C., Alkhatib, G., Briedis, D., Appel, M., Norton, E. and Papoletti, E., 1992, Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins, Virology, 187:321.
Ulaeto, D., Wallace, L., Morgan, A. J., Morein, B. and Rickinson, A. B., 1988, In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T-cell clones specific for the major envelope glycoprotein, gp340, Eur. J. Immunol., 18:1689.
Wallace, L. E., Wright, J., Ulaeto, D. O., Morgan, A. J. and Rickinson, A. B., 1991, Identification of CD4+ T cell epitopes of the candidate Epstein-Barr virus vaccine glycoprotein gp340, I. Virol., 65:3821.
Watkins, D. I., Hodi, F. S. and Letvin, N. L., 1988, A primate species with a limited major histocompatability complex class I polymorphism, Proc. Natl. Acad. Sci. USA, 85:7714.
Whang, Y., Silberklang, M., Morgan, A., Munshi, S., Lenny, A. B., Ellis, R. W. and Kieff, E., 1987, Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells, J. Virol., 61:1796.
Young, L. S., Finerty, S., Rickinson, A. B. and Morgan, A. J., 1988, Epstein-Barr virus gene expression in lymphomas induced by the virus in the cottontop tamarin, J. Virol., 63:1967.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Morgan, A.J. (1993). Progress in the Development of Epstein-Barr Virus Vaccines. In: Gregoriadis, G., McCormack, B., Allison, A.C., Poste, G. (eds) New Generation Vaccines. NATO ASI Series, vol 261. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2948-4_17
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2948-4_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6281-4
Online ISBN: 978-1-4615-2948-4
eBook Packages: Springer Book Archive